Clinical curative effect analysis of vena cava filter placement and thrombolytic therapy combined with Rivaroxaban for acute deep venous thrombosis
10.3969/j.issn.1002-1671.2017.11.029
- VernacularTitle:滤器、溶栓联合利伐沙班对急性下肢DVT的临床疗效分析
- Author:
Kun YUE
1
;
Xiaobing LI
;
Jianwei CHEN
;
Xiaoyu LIU
;
Weidong GONG
Author Information
1. 空军军医大学唐都医院介入放射科
- Keywords:
acute deep vein thrombosis of the lower extremity;
inferior vena cava filter;
transcatheter persistent thrombolysis;
Rivaroxaban
- From:
Journal of Practical Radiology
2017;33(11):1758-1760
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical curative effect of inferior vena cava filter placement and catheter direct thrombolytic therapy combined with anticoagulant therapy with Rivaroxaban for deep venous thrombus (DVT) of the lower extremity.Methods 40 patients with acute lower extremity DVT were collected,after the inferior vena cava filter placement,thrombolytic catheter were placed in femoral and iliac vein occlusion,and urokinase was continuously infused through the catheter 24 h.Anticoagulant therapy with Rivaroxaban tablets started when the patient was diagnosed with the disease.We evaluated the short-term and long-term efficacy of the treatment from the iliac femoral vein patency,limb circumference and complications.Results 40 patients were successfully implanted the filter,38 patients were successfully removed the filter after 21 days.The clinical symptoms were relieved after 7 days of treatment,and the iliac femoral vein blood flow was basically recovered.Before and after treatment,the limb circumference was significantly reduced (P＜0.05).No serious complications occurred during the treatment period.Following up in 6 months,the rate of iliac vein occlusion and pigmentation were 2.5 ％ (1/40)and 2.5 ％ (1/40)respectively.Following up in 12 months,the rate of iliac vein occlusion and pigmentation were 7.5 ％ (3/40) and 5.0 ％ (2/40)respectively.Conclusion For treatment of acute DVT of the lower extremity,inferior vena cava filter placement and catheter direct thrombolytic therapy combined with anticoagulant therapy with Rivaroxaban can achieve satisfactory clinical curative effect,which is clinically safe and feasible.
